Evidence map›Paper›PMID 41269415›Full record

ArticleMolecular neurobiology2025

Associations Between APOE Polymorphisms, Neurological Symptoms, and Cognitive Assessments in Long COVID Patients: An Analysis of SNPs rs7412 and rs429358.

Isadora de Almeida Gomes, Pedro Braga-Neto, Thiago Loreto Matos, Emerson Lucena da Silva, Lais Lacerda Brasil de Oliveira, Luina Benevides Lima, José Wagner Leonel Tavares-Júnior, Alissa Elen Formiga Moura, Marcello Holanda de Andrade, Thaís de Maria Frota Vasconcelos and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Isadora de Almeida GomesPharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, Ceará, Brazil.
Pedro Braga-NetoNeurology Division, Department of Clinical Medicine, Federal University of Ceará, Fortaleza, Ceará, Brazil.
Thiago Loreto MatosPharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, Ceará, Brazil.
Emerson Lucena da SilvaPharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, Ceará, Brazil.
Lais Lacerda Brasil de OliveiraPharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, Ceará, Brazil.
Luina Benevides LimaPharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, Ceará, Brazil.
José Wagner Leonel Tavares-JúniorNeurology Division, Department of Clinical Medicine, Federal University of Ceará, Fortaleza, Ceará, Brazil.
Alissa Elen Formiga MouraNeurology Division, Department of Clinical Medicine, Federal University of Ceará, Fortaleza, Ceará, Brazil.
Marcello Holanda de AndradeNeurology Division, Department of Clinical Medicine, Federal University of Ceará, Fortaleza, Ceará, Brazil.
Thaís de Maria Frota VasconcelosNeurology Division, Department of Clinical Medicine, Federal University of Ceará, Fortaleza, Ceará, Brazil.
Reinaldo Barreto OriáNeurology Division, Department of Clinical Medicine, Federal University of Ceará, Fortaleza, Ceará, Brazil.
Danilo Nunes OliveiraNeurology Division, Department of Clinical Medicine, Federal University of Ceará, Fortaleza, Ceará, Brazil.
Manoel Alves Sobreira-NetoNeurology Division, Department of Clinical Medicine, Federal University of Ceará, Fortaleza, Ceará, Brazil.
Pedro Filho Noronha SouzaPharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, Ceará, Brazil.
Maria Elisabete Amaral de MoraesPharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, Ceará, Brazil.
Felipe Pantoja MesquitaPharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, Ceará, Brazil. felipemesquita05@gmail.com.
Raquel Carvalho MontenegroPharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, Ceará, Brazil. rcm.montenegro@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long COVID has been associated with persistent neurological symptoms that impair cognitive function and quality of life, raising questions about the role of genetic factors in symptom severity and persistence. Apolipoprotein E (APOE) polymorphisms, known for their relevance in neurodegenerative diseases, may significantly influence neurological outcomes in long COVID patients. This study aimed to investigate the relationship between APOE polymorphisms, specifically single nucleotide polymorphisms (SNPs) rs7412 and rs429358, and neurological and cognitive symptoms in long-term COVID patients. APOE genotypes were identified through the analysis of SNPs rs7412 and rs429358. Cognitive and behavioral assessments were conducted using the Mini-Mental State Examination (MMSE), the Pfeffer Functional Activities Questionnaire, the Beck Inventory for mood assessment and the Epworth Sleepiness Scale (ESS). Statistical analyses included Mann-Whitney U test, chi-square or Fisher's exact test, and odds ratio calculation, using R Studio and GraphPad Prism. The results indicated that the ε2ε3 genotype was associated with lower scores on the BECK, suggesting fewer depressive symptoms, while the ε3ε3 genotype was linked to an increase in depressive symptoms. Furthermore, analyses of APOE alleles showed an opposite pattern concerning daytime sleepiness: carriers of the ε2 allele exhibited greater daytime sleepiness, whereas ε3 allele carriers reported less sleepiness, as measured by the ESS. The analysis of the rs7412 SNP revealed significant impacts on both BECK and ESS scores. These findings suggest that APOE polymorphisms, particularly the ε2 and ε3 alleles, play a crucial role in modulating neurological and cognitive symptoms associated with long COVID. The results highlight the potential of genetic screening to identify patients at higher risk of persistent cognitive and emotional alterations, emphasizing the importance of personalized management strategies and the need for further research in diverse populations.

Indexed as

Apolipoproteins ECognitionCOVID-19Polymorphism, Single NucleotideAdultAgedAllelesFemaleGenetic Association StudiesGenetic Predisposition to DiseaseGenotypeHumansMaleMiddle AgedApoE protein, humanApolipoproteins ECOVID-19Neurological conditionPolymorphism

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.